Welcome to our dedicated page for Liquidia Corporation SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Liquidia’s clinical milestones can feel like navigating a labyrinth of FDA language, trial statistics, and licensing footnotes. Each new Liquidia 8-K material events explained notice might include pivotal updates on YUTREPIA’s path to approval, while a single Form 4 could show an insider buying shares ahead of a data read-out. Our AI-driven platform decodes those complexities so you can focus on what matters, delivering Liquidia SEC filings explained simply the moment they hit EDGAR.
Stop skimming hundred-page PDFs. Stock Titan’s engine extracts the cash-runway tables from every Liquidia quarterly earnings report 10-Q filing, highlights trial spend buried inside the Liquidia annual report 10-K simplified, and flags Liquidia proxy statement executive compensation details side by side with peer data. Need to watch executive moves? Receive Liquidia Form 4 insider transactions real-time alerts that list each Liquidia executive stock transactions Form 4 in context—share price, option type, and historical buying patterns.
Whether you’re comparing treprostinil royalty streams or assessing dilution risk from future capital raises, our coverage spans every filing type—from 10-K, 10-Q, and 8-K to Section 16 reports—updated in seconds. AI-powered summaries, keyword search across historical documents, and exportable tables let you perform rapid Liquidia earnings report filing analysis without specialized training. Use cases include:
- Monitoring Liquidia insider trading Form 4 transactions before trial announcements
- Understanding Liquidia SEC documents with AI for quicker valuation models
- Tracking manufacturing scalability disclosures tied to PRINT® technology
Liquidia Corporation (LQDA) filed a Form 144 disclosing a proposed sale of 7,500 common shares with an aggregate market value of $220,650. The shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an approximate sale date of 09/03/2025. The securities were acquired as Restricted Stock Units from Liquidia Corporation on 06/16/2025, and the filing reports payment/vesting on that same date. The filing shows 86,091,454 shares outstanding. The form indicates no securities sold by the same person in the past three months. Several standard filer and issuer contact fields in the submitted tables appear blank.
Scott Moomaw, Chief Commercial Officer of Liquidia Corporation (LQDA), reported multiple equity transactions. On 08/29/2025 he received 1,875 restricted stock units (RSUs) that convert one-for-one into common shares, increasing his RSU holdings. On 09/02/2025 he sold a total of 70,692 shares in three transactions: 692 shares at $29.05 and 8,315 plus 61,685 shares at a volume-weighted average price of $28.6224. The Form 4 notes the sales were effected pursuant to Rule 10b5-1 trading plans and some shares were sold to cover taxes related to RSU settlements. Following these transactions he beneficially owned 155,254 common shares (direct).
Russell Schundler, General Counsel of Liquidia Corporation (LQDA), reported multiple transactions in company equity. On 08/29/2025, 2,344 restricted stock units (RSUs) vested and converted into 2,344 shares. On 09/02/2025, 1,063 shares were sold at $29.05 per share under a Rule 10b5-1 plan to cover taxes related to RSU settlement. After these transactions, Schundler beneficially owned 580,098 shares directly and 14,500 shares indirectly (by spouse), for a total of 594,598 shares reported. The filing notes multiple prior RSU grants (2022, 2023, 2024, 2025) with portions unvested and 11,869 shares held under the employee stock purchase plan.
Liquidia Corporation insider Sarah Krepp, Chief Human Resource Officer, reported a small disposition of company common stock under a Rule 10b5-1 trading plan. The Form 4 shows a sale on 08/29/2025 of 209 shares at $29.05 per share, executed pursuant to a 10b5-1 plan adopted December 15, 2023, and the transaction was to cover taxes on RSU settlements. After the sale, Krepp beneficially owns 143,130 shares, including multiple unvested RSU tranches (specified amounts) and 5,312 shares from the 2020 Employee Stock Purchase Plan.
Michael Kaseta, Chief Financial Officer and Chief Operating Officer of Liquidia Corporation (LQDA), reported equity transactions in a Form 4. On 08/29/2025 he had 2,344 restricted stock units (RSUs) convert into common stock, increasing his beneficial ownership to 359,596 shares. Pursuant to a Rule 10b5-1 plan, he sold 1,148 shares on 09/02/2025 at $29.05 per share to cover taxes, leaving 358,448 shares beneficially owned. The filing details prior RSU grants: a 37,500 RSU grant on 01/16/2022 of which 32,813 had vested, multiple grants in 2023–2025 with substantial unvested RSU balances, and 11,257 shares held under the 2020 Employee Stock Purchase Plan.
Liquidia Corp Chief Accounting Officer Dana Boyle reported a transaction under a Rule 10b5-1 plan: on 08/29/2025 she sold 296 shares of common stock at $29.05 per share to cover tax withholding related to vested restricted stock units. Following the sale, Boyle beneficially owns 186,649 shares, which include multiple unvested RSU grants from 2022 through 2025 and 11,869 shares acquired under the 2020 Employee Stock Purchase Plan. The filing is a Form 4 and was signed on 09/03/2025.
Paul B. Manning, a director of Liquidia Corp (LQDA), reported multiple sales of Common Stock in late August and early September 2025. The Form 4 shows sales on 08/28/2025 (154,337 shares at a weighted average $27.94), 08/29/2025 (188,232 shares at $27.62 weighted average), and two sales on 09/02/2025 (254,038 shares at $28.67 weighted average and 74,230 shares at $29.14 weighted average). The filing lists several holdings held indirectly through trusts and entities (including PBM 2024 GRAT, PBM 2000 Trust, BKB Growth Investments, PBM Capital Finance, and PD Joint Holdings) and notes 3,131,794 shares disposed of in total on one line and various indirect ownership amounts disclosed in footnotes.
Insider transactions by Jason Adair, Chief Business Officer of Liquidia Corporation (LQDA). The Form 4 reports vesting and sales of restricted stock units (RSUs) and open-market sales made under Rule 10b5-1 plans. On 07/11/2025 Mr. Adair had 3,906 RSUs converted to common stock. Subsequent sales: 26,057 shares sold on 08/28/2025 at a VWAP of $27.8564 and 451 shares sold on 09/02/2025 at $29.05. A 1,562-share RSU conversion occurred on 08/29/2025. The filing discloses total beneficial ownership adjustments including unvested RSU balances from grants dated 01/11/2023, 07/06/2023, 01/11/2024 and 01/11/2025 and 10,746 shares from the 2020 ESPP; corrected prior filing counts are also noted.
Dr. Rajeev Saggar, Chief Medical Officer of Liquidia Corporation (LQDA), reported a sale of 20,000 shares of common stock on 08/28/2025. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on May 29, 2025 and produced a volume-weighted average price of $27.8536 (prices on the day ranged from $27.22 to $28.53). After the transaction, Dr. Saggar beneficially owned 249,727 shares, which include multiple unvested restricted stock unit (RSU) grants totaling 138,356 unvested RSUs from grants dated January 11, 2023, 2024 and 2025, plus 7,131 shares acquired under the company ESPP. The Form 4 is signed by Dr. Saggar on 09/02/2025.
Form 144 notice for Liquidia Corporation (LQDA) shows a proposed sale of 70,000 common shares through Morgan Stanley Smith Barney at an aggregate market value of $1,937,600, with an approximate sale date of 09/02/2025 on NASDAQ. The shares were acquired in three tranches: 8,315 via an Employee Stock Purchase Plan on 08/31/2022, 7,650 as Performance Stock Units on 11/10/2021, and 54,035 as Restricted Stock Units on 07/11/2024; payment where applicable was in cash or recorded as N/A. The filing lists two recent sales by the same seller, totaling 11,453 shares for gross proceeds of $181,453.48. The filer represents they are unaware of undisclosed material adverse information.
FAQ
What is the current stock price of Liquidia Corporation (LQDA)?
What is the market cap of Liquidia Corporation (LQDA)?
